Selective estrogen receptor modulators (SERMs) PDF

Preview

Summary

Download Selective estrogen receptor modulators (SERMs) PDF

Description

Drug Information Table Selective estrogen receptor modulators (SERMs) – Raloxifene (Evista) THERAPEUTIC USE

• Postmenopausal osteoporosis—prevention and treatment • Reduces risk of estrogen receptor-positive breast cancer

ADVERSE DRUG REACTIONS

• Increased risk of deep vein thrombosis (DVT) and pulmonary emboli • Hot flashes • Stroke

INTERVENTIONS

• Observe for signs and symptoms of thromboemboli. • Use lightweight covers over clients. • Monitor bone density.

ADMINISTRATION

• Give orally daily. • May give with or without food.

CLIENT INSTRUCTIONS

• • • •

CONTRAINDICATIONS

• Teratogenic • Lactation • Current and past history of deep vein thrombosis

PRECAUTIONS

• Estrogen therapy • Hyperlipidemia

INTERACTIONS

• Concurrent administration with estrogen is not recommended.

Contact provider if client experiences pain in calf or difficulty breathing. Do not take estrogen replacement therapy during treatment. Warn clients that hot flashes may occur. Encourage clients to consume adequate amounts of calcium and vitamin D • Encourage clients to perform weight-bearing exercises (brisk walking, stair climbing) daily. • If premenopausal and using raloxifene to prevent breast cancer, use contraception and do not breastfeed during treatment. • Do not take estrogen replacement therapy during treatment.

Assessment Technologies Institute: Pharmacology Made Easy 4.0

1...